- Accession Number
Drug Drug Description Ezetimibe A cholesterol absorption inhibitor used to lower total cholesterol, LDL-C, Apo-B, and non-HDL-C in primary hyperlipidemia and familial cholesterolemia. Ximelagatran For the treatment of acute deep vein thrombosis. Cobimetinib An antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma. Azelnidipine For the treatment of hypertension. Baricitinib A Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist. PF-04418948 Pf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers). RRx-001 RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others. Itacitinib Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others. Siponimod A medication used to treat relapsing multiple sclerosis. PF-03635659 Pf03635659 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease. Atecegatran metoxil Atecegatran metoxil has been used in trials studying the basic science and prevention of Nonvalvular Atrial Fibrillation, Persistent or Permanent Nonvalvular Atrial Fibrillation, and Persistent or Permanent Non-valvular Atrial Fibrillation. JNJ-41443532 JNJ-41443532 has been used in trials studying the basic science and treatment of Diabetes Mellitus, Type 2. Melagatran Not Annotated AZD-1656 AZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes). PF-5190457 PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations In Healthy Volunteers). Aclimostat Aclimostat is under investigation in clinical trial NCT03254368 (Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes). Ceralifimod Ceralifimod is under investigation in clinical trial NCT01226745 (Phase 2 Extension Trial in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)).
- Drugs & Drug Targets